Form D · Pharmaceuticals

OCARO PHARMACEUTICALS INC.

Greensboro, NC · CIK 0001165139

Offering snapshot reported Nov 15, 2022 · SEC filing

Reported sold
$610K
Offering amount: $610K
Investors reported
12
Form D · investor count
Minimum accepted
$30K
Reported outside-investor minimum
First sale
Nov 1, 2022
As reported in this filing

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Nov 15, 2022Initial$610,000No comparison12SEC filing
Apr 1, 2009Initial$5,175,744No comparisonNot reportedSEC filing
Nov 9, 2007PaperNot reportedNo comparisonNot reportedSEC filing
Nov 9, 2007PaperNot reportedNo comparisonNot reportedSEC filing
Nov 9, 2007PaperNot reportedNo comparisonNot reportedSEC filing
Nov 9, 2007PaperNot reportedNo comparisonNot reportedSEC filing
Oct 15, 2007PaperNot reportedNo comparisonNot reportedSEC filing
Dec 15, 2005PaperNot reportedNo comparisonNot reportedSEC filing

Offering details

Securities
Equity, Debt
Exemptions
06b
Duration over one year
No
Business combination
No
Sales commissions
$0
Finders' fees
$0
Form D file number
021-464849

Source: Form D, filed Nov 15, 2022. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Eric Barnett Executive
Luther H. Hodges, Jr. Director
Andy Jane Director
Roland Johnson Director, Executive
Thomas R. Sloan Director
Lanty Smith Director
Kenneth Yates Director
Bill Yates Director

Issuer details

Industry: Pharmaceuticals (See others in industry)

Address:
204 Muirs Chapel Road Suite 202
Greensboro, NC, 27410